Evaluating the neuroprotective impact of senolytic drugs on human vision
Abstract Glaucoma, a chronic neurodegenerative disease of retinal ganglion cells (RGCs), is a leading cause of irreversible blindness worldwide. Its management currently focuses on lowering intraocular pressure to slow disease progression. However, disease-modifying, neuroprotective treatments for g...
Guardado en:
Autores principales: | Nevin W. El-Nimri, Spencer M. Moore, Linda M. Zangwill, James A. Proudfoot, Robert N. Weinreb, Dorota Skowronska-Krawczyk, Sally L. Baxter |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c1aad6bcbf894135b674b4437693f52f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Senolytics: A Novel Strategy for Neuroprotection in ALS?
por: Alexandra Maximova, et al.
Publicado: (2021) -
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC
por: Leleesha Samaraweera, et al.
Publicado: (2017) -
Senolytic Therapy for Cerebral Ischemia-Reperfusion Injury
por: Songhyun Lim, et al.
Publicado: (2021) -
Identification and characterization of Cardiac Glycosides as senolytic compounds
por: Francisco Triana-Martínez, et al.
Publicado: (2019) -
Long-term treatment with senolytic drugs Dasatinib and Quercetin ameliorates age-dependent intervertebral disc degeneration in mice
por: Emanuel J. Novais, et al.
Publicado: (2021)